Assignee
GARCIA-ECHEVERRIA CARLOS
FR·4 granted patents·15 pending applications·45 citations·filing 2005–2016
Top patents by PatentIndex Score
19 records- 0190US8431592B21,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2011·Granted Apr 30, 2013·13 cites·5 claims
- 0289US8263590B2Pyrimidine derivativesGARCIA-ECHEVERRIA CARLOS·Filed 2011·Granted Sep 11, 2012·19 cites·13 claims
- 0383US9370508B2Imidazoquinolines as dual lipid kinase and mTOR inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2008·Granted Jun 21, 2016·13 cites·1 claims
- 0468US2011236379A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2009·Application pending·0 cites
- 0558US2011033453A1Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family membersGARCIA-ECHEVERRIA CARLOS·Filed 2009·Application pending·0 cites
- 0658US2011020338A15Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic ProcessesGARCIA-ECHEVERRIA CARLOS·Filed 2009·Application pending·0 cites
- 0756US2012207751A1Imidazoquinolines as lipid kinase inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
- 0855US2012219550A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
- 0954US9241939B2Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathwayGARCIA-ECHEVERRIA CARLOS·Filed 2014·Granted Jan 26, 2016·0 cites·4 claims
- 1052US2015209362A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2015·Application pending·0 cites
- 1151US2014161722A1Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family membersGARCIA-ECHEVERRIA CARLOS·Filed 2014·Application pending·0 cites
- 1248US2012282252A15Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic ProcessesGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
- 1347US2016346292A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2016·Application pending·0 cites
- 1447US2014242088A1Hsp90 inhibitor combinationsGARCIA-ECHEVERRIA CARLOS·Filed 2014·Application pending·0 cites
- 1547US2014057904A1Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathwayGARCIA-ECHEVERRIA CARLOS·Filed 2013·Application pending·0 cites
- 1645US2016136175A1Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2015·Application pending·0 cites
- 1741US2017049781A1Hsp90 inhibitor combinationsGARCIA-ECHEVERRIA CARLOS·Filed 2016·Application pending·0 cites
- 1840US2009149469A1Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2005·Application pending·0 cites
- 1937US2014275078A1Compositions and methods for treating cancer using pi3kb inhibitor and mapk pathway inhibitor, including mek and raf inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GARCIA-ECHEVERRIA CARLOS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →